Salute e Benessere

Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the…

The Company expects that it will take approximately eight months to complete process development and manufacturing of KLTO-202, and about four to six months to conduct meetings with FDA, complete all FDA-mandated animal safety studies, file an investigational new drug application (IND), train and prepare clinical sites where the Phase I/II studies can be conducted, and then begin the single-dose gene therapy studies in ALS patients by the third quarter of next year. The Company will work with…
PR Newswire
30/06/2025

Bastide Groupe Sells Baywater Healthcare To Sapio Group

Crewe, United Kingdom & Monza, Italy - 30th June 2025 Bastide le Confort Medical SA (hereinafter “Groupe Bastide”) today announced that it has agreed to the sale of its subsidiary Baywater Healthcare UK Limited (hereinafter “Baywater Healthcare” or “Company”), a leading provider of home oxygen services (“HOS”) and respiratory homecare in the UK, to the Sapio S…
Actusnews Wire
30/06/2025

Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial

Press ReleaseNicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial Results expected mid-August to mid-September 2025New Drug Application (NDA) submission in the U.S. targeted for H1 2026June 30, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the last patient has completed the Denali Phase 3 trial, evaluating the...
Nasdaq GlobeNewswire
30/06/2025

Press release: Availability of the Q2 2025 Aide mémoire

Availability of the Q2 2025 Aide mémoireParis, France – June 30, 2025. Sanofi announced today that its Q2 2025 Aide mémoire is available on the "Investors" page of the company's website: Second quarter 2025 (sanofi.com) As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items, as well as the foreign currency impact and share count. Sanofi's second...
Nasdaq GlobeNewswire
30/06/2025

PAP Devices Market to Reach $6.97 Billion by 2032, Growing at a CAGR of 5.2%…

The consistent growth of the PAP devices market is driven by increasing prevalence of respiratory and sleeping disorders amid rising global aging population suffering from respiratory conditions. The market's expansion is fueled by introduction of new sleep apnea devices, growing awareness about adverse impacts of untreated sleep apnea, favorable reimbursement policies for sleep apnea therapies, and expanding out-of-hospital healthcare preferences across key global markets. The consistent...
PR Newswire
30/06/2025

PlaDeo: Middle East Launch of the World's First Bio-Plasma Deodorant Device

In a region where high temperatures, humidity, and modest dress norms pose unique challenges for personal hygiene, PlaDeo offers a timely, science-backed alternative. The device uses reactive oxygen species (ROS) — specifically hydroxyl radicals (OH⁻) and superoxide ions (O₂⁻) — to neutralize odor-causing bacteria directly on the skin. No alcohol. No aluminum. No synthetic fragrances. Just clean, skin-safe, and non-invasive odor control. In a region wherehigh temperatures, humidity, and...
PR Newswire
30/06/2025

Changes to the Roche Enlarged Corporate Executive Committee

Roche CEO Thomas Schinecker: “Hans is an exceptional scientist who has been instrumental in translating cutting-edge science into improved patient outcomes. Under his leadership, the pRED organisation has accelerated several potentially transformational medicines into the final phase of development that will shape the company for the years to come. It has been a pleasure working with him and I am thankful for his many contributions to our company and patients. While he will step down from...
Nasdaq GlobeNewswire
30/06/2025

Press Release: Riliprubart granted orphan drug designation in Japan for chronic…

Riliprubart granted orphan drug designation in Japan forchronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a potential first-in-class treatmentJapanese Ministry of Health, Labour and Welfare decision adds to similar designations in the US and Europe, underscoring global regulatory recognition of the potential for riliprupart to address significant unmet medical needs for people living with this rare...
Nasdaq GlobeNewswire
30/06/2025

Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine…

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – Addex Therapeutics(SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced it has led a CHF 2 million investment in Stalicla, a clinical-stage company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders. Stalicla will use the financing to advance its...
Nasdaq GlobeNewswire
30/06/2025

Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance…

Press ReleaseStalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder ProgramsGeneva, Switzerland – June 30, 2025– STALICLA SA, a Geneva-based clinical-stage biotech company pioneering precision medicine for neurodevelopmental and neuropsychiatric disorders, today announced the successful closing of a CHF 2 million financing led by Addex Therapeutics. This financing will sustain operations and program development in...
Nasdaq GlobeNewswire
30/06/2025

A factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform…

Ad hoc announcement pursuant to Art. 53 LR Potential first-ever vaccine directed againstC. difficilebacteria and spores induces positive antigen titers in humans that recognize the bacteriaInitial data from healthy participants confirm the vaccine is safe, well-tolerated and immunogenicThe study serves as a clinical validation for Idorsia's revolutionary synthetic glycan vaccine technologyIdorsia will now activate partnering discussions to advance as fast as possible the...
Nasdaq GlobeNewswire
30/06/2025

Turning the Tide on Obesity, Digestive Diseases and Cancers: EU Urged to Act Now

MEP Alessandra Moretti noted that non-communicable diseases (NCDs) account for 90% of EU deaths but receive just 2.8% of health budgets. She emphasised the need for enhanced screening and increased research funding. MEP Alessandra Moretti noted that non-communicable diseases (NCDs) account for 90% of EU deaths but receive just 2.8% of health budgets. She emphasised the need for enhanced screening and increased research funding. In a keynote address, Dr. Kremlin Wickramasinghe of WHO Europe...
PR Newswire
30/06/2025

ESHRE 41st Annual Meeting: Older paternal age linked to higher miscarriage risk…

The retrospective study analysed 1,712 first oocyte donation cycles conducted between 2019 and 2023 across six IVF centres in Italy and Spain. All cycles used fresh donor oocytes and frozen sperm from male partners, with only the first single blastocyst transfer included. Female recipients had a mean age of 43.3 years. The retrospective study analysed 1,712 first oocyte donation cycles conducted between 2019 and 2023 across six IVF centres inItalyandSpain. All cycles used fresh donor...
PR Newswire
30/06/2025

Medical Device Contract Manufacturing Market to Reach $171.19 Billion by 2032…

The growth of the medical device contract manufacturing market is driven by increasing preference for outsourcing design, development, and manufacturing in the MedTech sector amid rising regulatory complexity and cost optimization needs. The market's expansion is fueled by advanced manufacturing technologies, changing regulatory landscapes requiring specialized expertise, Industry 4.0 adoption, and growing healthcare expenditure across key global markets. The growth of themedical device...
PR Newswire
29/06/2025

Clinical Trials Market Size, Share, Growth, Report 2025 To 2034

The global clinical trials market size was valued at USD 60.56 billion in 2024 and is expected to be worth around USD 95.60 billion by 2034, growing at a compound annual growth rate (CAGR) of 4.67% over the forecast period 2025 to 2034.
Cervicorn Consulting
29/06/2025

ESOT Congress 2025: Scientists create functional human islets in 3D printing…

Traditional islet transplants are typically infused into the liver, a process that can result in significant loss of cells and limited long-term success. In contrast, the 3D-printed islets were designed to be implanted just under the skin, a simple procedure requiring only local anaesthesia and a small incision. This minimally invasive approach could offer a safer and more comfortable option for patients. Traditional islet transplants are typically infused into the liver, a process that can...
PR Newswire
29/06/2025

FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and…

The approval is based on results of the pooled data from two pivotal studies, the Phase 3 study (NCT05001737) and NI-0501-06 (NCT03311854). 54 percent (21/39) of patients had a complete response at Week 8, and 82% (32/39) achieved clinical MAS remission (VAS ≤1 cm) at Week 8. Safety and tolerability were consistent with previous clinical studies. In patients with HLH/MAS in Still's disease, the most common adverse events (≥20%) were viral infections, including cytomegalovirus infection or…
PR Newswire
28/06/2025

Information on the total number of voting rights and shares

REGULATED INFORMATIONInformation on the total number of voting rights and sharesMont-Saint-Guibert(Belgium), June 27, 2025 , 10:30 pm CET / 4:30 pm ET –In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 6,431,121.38 Total number of securities carrying voting rights: 37,435,640 (all ordinary...
Nasdaq GlobeNewswire
27/06/2025

Ophthalmology Drugs Market worth $26.28 billion by 2030 with 6.1% CAGR |…

Browse in-depth TOC on "Ophthalmology Drugs Market" Browse in-depth TOC on "Ophthalmology Drugs Market" 370 - Tables 55 - Figures 328 - Pages By route of administration,Drugs administered via the intravitreal route are commonly used to treat a wide range of ophthalmological conditions. Notably, every major breakthrough medication for retinal diseases—including ranibizumab, aflibercept, faricimab, brolucizumab, pegcetacoplan, avacincaptad pegol, and...
PR Newswire
27/06/2025

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical…

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA ®(nusinersen) Final results from the landmark NURTURE study highlight the profound impact of early treatment with 12 mg SPINRAZA in clinically presymptomatic SMA with 92% of children achieving the ability to walk independentlyCAMBRIDGE, Mass., June27, 2025(GLOBE...
Nasdaq GlobeNewswire
27/06/2025

Navamedic ASA: First approval of the medical device OraFID® as primary package…

Treatments with a narrow therapeutic window can benefit from hyper-fractioning of the dose, by dividing it into minitablets, each containing a fraction of the dose. Treatments with a narrow therapeutic window can benefit from hyper-fractioning of the dose, by dividing it into minitablets, each containing a fraction of the dose. OraFID® works with a couple of twists of the hands and ejects an exact number of minitablets. It is approved as an integral combination product for Flexilev®,...
PR Newswire
27/06/2025

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to…

—Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones——BioCryst plans to use proceeds to retire all remaining term debt, which will eliminate approximately $70 million of future interest payments over remaining life of the loan——With this transaction, BioCryst expects to end 2027 with approximately $700 million in cash and no term debt (an increase of $400 million from prior...
Nasdaq GlobeNewswire
27/06/2025

Zentiva calls for Pause - Repair - Relaunch of the Urban Wastewater Treatment…

Zentiva's CEO, Steffen Saltofte, joined a panel on the topic "Delivering access to medicines in the context of the Clean Transition and One Health" - advocating for a clean transition that does not compromise access to medicines. With the support of local associations, German Progenerika and Czech CAFF, he presented reality checks from Germany and the Czech Republic, two of Zentiva's key markets. Zentiva's CEO,Steffen Saltofte, joined a panel on the topic "Delivering access to…
PR Newswire
27/06/2025

Coway Launches The Airmega 50, Its Most Compact Cylindrical Air Purifier To Date

According to the European Academy of Allergy and Clinical Immunology (EAACI), over 150 million Europeans suffer from chronic allergic diseases, making compact air purifiers an increasingly practical choice for relief from airborne allergens and all-round healthier living. According to theEuropean Academy of Allergy and Clinical Immunology (EAACI), over 150 million Europeans suffer from chronic allergic diseases, making compact air purifiers an increasingly practical choice for relief from...
PR Newswire
27/06/2025
Altri  Comunicati